TITLE

OSTEOARTHROPATHY IN MUCOPOLYSACCHARIDOSIS TYPE II

AUTHOR(S)
NASCU, IOANA; GRIGORESCU-SIDO, PAULA; AL-KHZOUZ, CAMELIA; BUCERZAN, SIMONA; DENES, CARMENCITA; LAZEA, CECILIA
PUB. DATE
September 2013
SOURCE
Clujul Medical;2013, Vol. 86 Issue 3, p270
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction. Mucopolysaccharidosis type II (MPS type II, Hunter syndrome) is a rare (~ 1/1500.000), X-linked inherited disorder (affects boys) due to deficiency of the lysosomal enzyme iduronate sulfatase (Xq.28). The complex clinical picture includes osteoarthropathy with a tendency to flexion stiffness and disability. In our country, the specific diagnosis and enzyme replacement therapy (ERT), are recently available in the Center for Genetic Pathology Cluj. Objectives. Assessment of clinical features, radiological and imaging of osteoarthropathy in MPS type II and their evolution under ERT. Material and methods. The study included 9 male patients with a suggestive clinical picture of MPS type II; the diagnosis was confirmed by enzymatic assay and the patients were treated with ERT. Osteoarthropathy was assessed before treatment: a) clinical tests (joint goniometry, walking test) and b) radiology (X-rays of the hand and wrist, spine and pelvis), bone densitometry in five patients. Clinical tests were repeated after therapy. Results. Chronic osteoarthropathy was present in all patients. Joint mobility was reduced with quasi stationary trend after 12 months of treatment. The walking test was improved after treatment. Radiological assessment revealed: hand bones changes, delayed bone age, vertebral changes, pelvis changes, kipho-scoliosis and aseptic necrosis of the femoral head in 100%, 88%, 88%, 55% and 11% respectively. Bone mineral density was normal in five of the nine patients evaluated. Conclusions. Chronic osteoarthropathy with flexion stiffness is an essential component of the clinical picture of MPS type II. ERT allows an improvement/arrest of evolution (depending on disease severity and time of initiating therapy).
ACCESSION #
90648442

 

Related Articles

  • Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome). Young Bae Sohn; Sung Yoon Cho; Sung Won Park; Su Jin Kim; Ko, Ah-Ra; Kwon, Eun-Kyung; Han, Sun Ju; Jin, Dong-Kyu // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Background: Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by the deficiency of iduronate-2-sulfatase (IDS). In affected patients, glycosaminoglycan (GAG) accumulates in the lysosomes of many organs and tissues contributing to the...

  • A RARE CASE OF HUNTER SYNDROME -CASE REPORT. Melit, Lorena Elena; Marginean, Oana; Duicu, Carmen; Campean, Cristina; Marginean, Maria Oana // Romanian Journal of Pediatrics;2015, Vol. 64 Issue 1, p38 

    Mucopolysaccharidoses (MPSs) are a group of rare genetic disorders within the larger family of lysosomal diseases. MPSs disorders are caused by a deficiency in the activity of a specific lysosomal enzyme required for the degradation of glycosaminoglycans (GAGs). MPS type II, also called Hunter...

  • Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Jurecka, A.; Żuberuber, Z.; Opoka-Winiarska, V. // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 2, p62 

    A review of the article "Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature," by A. Jurecka and colleagues, which appeared in the periodical "Molecular Genetics and Metabolism" in 2012, is presented.

  • First Successful Bone Marrow Transplant Conducted by Artemis Doctors.  // eHEALTH;9/25/2015, p1 

    The article offers information on the first successful bone marrow transplant for genetic disorder Mucopolysaccharidosis II of patient Mohd. Farhin, resident of Bangladesh, by doctors of Artemis Hospitals at New Delhi in India, and presents the views of Vikas Dua, Consultant doctor, on the same.

  • Clinical utility gene card for: Mucopolysaccharidosis type II. Beck, Michael; Wijburg, Frits A; Gal, Andreas // European Journal of Human Genetics;Jan2012, Vol. 20 Issue 1, p-1 

    The article offers information on the disease Mucopolysaccharidosis type II. It mentions that the Mucopolysaccharidosis increases risk based on family history for a non-affected person. Further the clinical sensitivity of the disease can be dependent on variable factors such as age or family...

  • Botulinum Toxin Type A for the Treatment of Equinus Deformity in Patients With Mucopolysaccharidosis Type II. Nava, Esmeralda; Weber, Peter; Gautschi, Matthias; Nuoffer, Jean-Marc; Grunt, Sebastian // Journal of Child Neurology;Dec2012, Vol. 27 Issue 12, p1611 

    Mucopolysaccharidoses are lysosomal storage disorders that are caused by a deficiency in the enzymes that degrade glycosaminoglycans. The accumulation of glycosaminoglycans affects multiple systems, resulting in coarse facial features, short stature, organomegaly, and variable neurological...

  • Síndrome de Hunter. Asesoramiento a parejas y familiares con riesgo. Dilou, Yoni Tejeda; Monier, Yamira del Río; Valiente, Hilda Álvarez; Pradez, Dunia Coca; Núñez Copo, Antonio César // MEDISAN;2013, Vol. 17 Issue 8, p4046 

    Hunter syndrome or mucopolysaccharidosis Type II is an inborn error of mucopolyssacharide metabolism, caused by deficiency of the lysosomal enzyme iduronatesulfatase, which determines serious clinical manifestations, multisystem damage and premature death. Due to its hereditary character,...

  • The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation. Wiklund, Ingela; Raluy-Callado, Mireia; Chen, Wen-Hung; Muenzer, Joseph; Fang, Juanzhi; Whiteman, David // Quality of Life Research;Nov2014, Vol. 23 Issue 9, p2457 

    Purpose: The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire is a patient and parent-completed disease-specific instrument used in Hunter syndrome (mucopolysaccharidosis II), a rare paediatric progressive multi-systemic lysosomal storage disease. The...

  • Relationship of sleep to pulmonary function in mucopolysaccharidosis II. Pintos-Morell, Guillem // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 3, p86 

    The author reflects on the results of a study by J. Muenzer on the relationship between sleep and pulmonary function in mucopolysaccharidosis II (MPS). He discusses how the study was conducted which involved 30 treatment-naïve MPS II (Hunter syndrome) patients who underwent pulmonary function...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics